HELP NASDAQ
Cybin Inc. Common Stock
1W: -6.2%
1M: +17.3%
3M: +40.7%
YTD: -8.2%
$7.60
-0.10 (-1.30%)
Pre-Market: $7.54 (-0.06, -0.86%)
Weekly Expected Move ±11.5%
$6
$7
$8
$8
$9
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$471.1M
52W Range3.76-9.12
Volume860,387
Avg Volume1,214,209
Beta0.62
Dividend—
Analyst Ratings
Company Info
100 King Street West
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc. Common Stock
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Latest News
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Psychedelic drugmakers could get boost from HHS, VA memorandum
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Helus Pharma prices $50M public offering at $4.85 per share
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
Recent Insider Trades
No insider trades found